Inflammatory immune cells

Inflammatory immune cells encompass a broad category of leukocytes, including neutrophils, macrophages, and various lymphocyte subsets, that are central to the body's inflammatory response. These cells are responsible for identifying and eliminating pathogens, as well as initiating tissue repair following injury (StatPearls, 2023). However, when their activity becomes chronic or dysregulated, they drive the progression of numerous inflammatory and autoimmune diseases, such as rheumatoid arthritis and inflammatory bowel disease (NIH, 2022). In pharmacological terms, 'inflammatory immune cells' is not a single molecular target but a cellular environment containing numerous specific targets like receptors, enzymes, and signaling proteins. Therapeutic strategies often involve modulating these cells through the inhibition of cytokines, blockade of cell-surface markers, or interference with intracellular signaling pathways to restore immune homeostasis. Common drugs like corticosteroids provide broad suppression of these cells, while biologics target specific components like TNF-alpha or CD20 to achieve more precise modulation (PubMed, 2021). Consequently, while the term describes the biological context of many treatments, therapeutic intervention requires the identification of specific molecular targets within or on these cells.

Other names

LeukocytesWhite blood cellsInflammatory cellsMyeloid cellsLymphoid cellsImmune effectors

Drugs targeting inflammatory immune cells typically act by suppressing cellular activation, inhibiting the release of pro-inflammatory mediators (cytokines/chemokines), inducing cell depletion through antibody-dependent cellular cytotoxicity, or blocking recruitment and migration to sites of inflammation.